Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Mesothelioma data at ASCO 2020

Riyaz Shah • 19 Jun 2020
ASCO 2020
Lung Cancer Mesothelioma Antibodies Cisplatin Durvalumab Gemcitabine Pemetrexed Ramucirumab
RAMES

Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, highlights data coming from the RAMES study (NCT03560973) which evaluated the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in patients with relapsed, advanced mesothelioma. Dr Shah also highlights data coming from other recent studies in mesothelioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Riyaz Shah

3:17
Key insights from BTOG 2024: MARS 2 and HIT-MESO
Riyaz Shah • 18 Apr 2024
2:42
The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial
Riyaz Shah • 28 Apr 2023
2:35
CheckMate-816: what does the data tell us?
Riyaz Shah • 28 Apr 2023
2:49
SYSTEMS-2: radiotherapy in mesothelioma
Riyaz Shah • 28 Apr 2023

Related Videos

0:37
STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell • 18 Apr 2024
0:44
BTOG 2024: networking highlights and insights
Clive Peedell • 18 Apr 2024
0:49
Ongoing trials in thoracic radiotherapy: evaluating current role and significance
Thomas Newsom-Davis • 18 Apr 2024
4:20
Insights from BTOG 2024: advancements in TNM Staging, systematic staging, & immunotherapy strategies
Thomas Newsom-Davis • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals